Investigating how sex differences affect lung cancer progression and treatment responses
Official title: Development of Mouse and Humanized Models to Study Sex Disparities in Tumor Progression and Treatment of NSCLC
Funded at Virginia Commonwealth University · NIH-10889246 · Data updated 2026-11-12
This study is looking at how lung cancer behaves and responds to treatment differently in men and women, using special models to see how things like hormones and immune responses play a role, which could help improve care for everyone with lung cancer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $172,376 |
| NIH project number | 5R21CA283631-02 |
| Project ID | NIH-10889246 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with non-small cell lung cancer, particularly those interested in understanding how sex may influence their treatment outcomes.
✕Less likely to help
Patients with other types of cancer or those who do not have non-small cell lung cancer may not benefit from this research.
What this research studies
This research aims to understand the differences in lung cancer progression and treatment responses between males and females. By developing mouse and humanized models, the study will explore how factors like sex hormones and immune responses contribute to these disparities. The researchers will analyze tumor growth patterns and immune cell activity in both male and female models of non-small cell lung cancer (NSCLC). This approach may reveal critical insights into why men and women respond differently to various cancer treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective, sex-specific treatments for lung cancer.
How similar studies have gone: Previous research has indicated that sex differences can significantly impact cancer progression and treatment responses, suggesting that this approach may yield valuable insights.
Where this research is happening
-
Virginia Commonwealth University
Richmond, United States Active
Researchers
- Principal investigator: Landry, Joseph William — Virginia Commonwealth University
- Study coordinator: Landry, Joseph William
Related research
Other NIH-funded projects on the same topics.
-
7-marker protein test to predict NSCLC response to anti-PD-1 therapy
A Johns Hopkins team is testing a 7-marker protein test to help predict which advanced NSCLC patients will respond to anti-PD-1 therapy.
-
Barcoded tumor sequencing to map radiation-triggered immune effects in lung cancer
This project uses barcoded tumor models and sequencing to uncover how adding radiation to immunotherapy might spark whole-body immune attacks against non-small cell lung cancer.
-
Targeting the cancer-friendly secretory system in a common lung cancer cancer subtype
A study tests new ways to block the secretory system inside tumor cells to stop growth and spread in a major subtype of non-small cell lung cancer.
-
Predicting outcomes and side effects in stage III NSCLC with AI-driven imaging
A multimodal AI approach uses chest CT and tissue images to forecast how patients with unresectable stage III NSCLC will respond to durvalumab after chemoradiotherapy and who might develop pneumonitis.
-
ATM kinase as a target to help NSCLC with brain metastases respond to treatment
A study from Yale University tests whether blocking ATM kinase can delay or overcome treatment resistance in people with advanced non-small cell lung cancer that has spread to the brain and other organs.
-
Understanding how cancer-supportive tissue affects resistance to ALK and KRAS therapies
A research team will study how the tumor’s surrounding tissue changes as cancer cells become resistant to ALK and KRAS-targeted treatments, aiming to find better combination strategies for long-lasting remission.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.